Log in

NASDAQ:DMACDiaMedica Therapeutics Stock Price, Forecast & News

$6.75
-0.35 (-4.93 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.39
Now: $6.75
$7.13
50-Day Range
$4.46
MA: $5.57
$7.32
52-Week Range
$1.70
Now: $6.75
$8.80
Volume19,970 shs
Average Volume62,523 shs
Market Capitalization$95.44 million
P/E RatioN/A
Dividend YieldN/A
Beta2.86
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DMAC
CUSIPN/A
CIKN/A
Phone763-312-6755

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$0.64 per share

Profitability

Net Income$-10,650,000.00

Miscellaneous

Employees9
Market Cap$95.44 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive DMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.

DiaMedica Therapeutics (NASDAQ:DMAC) Frequently Asked Questions

How has DiaMedica Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

DiaMedica Therapeutics' stock was trading at $4.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DMAC shares have increased by 68.8% and is now trading at $6.75. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of DiaMedica Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DiaMedica Therapeutics.

When is DiaMedica Therapeutics' next earnings date?

DiaMedica Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for DiaMedica Therapeutics.

How were DiaMedica Therapeutics' earnings last quarter?

DiaMedica Therapeutics Inc (NASDAQ:DMAC) issued its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.09. View DiaMedica Therapeutics' earnings history.

What price target have analysts set for DMAC?

2 brokerages have issued 12 month price objectives for DiaMedica Therapeutics' shares. Their forecasts range from $14.00 to $15.00. On average, they anticipate DiaMedica Therapeutics' stock price to reach $14.50 in the next year. This suggests a possible upside of 114.8% from the stock's current price. View analysts' price targets for DiaMedica Therapeutics.

Has DiaMedica Therapeutics been receiving favorable news coverage?

News headlines about DMAC stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DiaMedica Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about DiaMedica Therapeutics.

Are investors shorting DiaMedica Therapeutics?

DiaMedica Therapeutics saw a drop in short interest during the month of June. As of June 30th, there was short interest totaling 19,600 shares, a drop of 14.0% from the June 15th total of 22,800 shares. Based on an average daily volume of 71,000 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the company's shares are sold short. View DiaMedica Therapeutics' Current Options Chain.

Who are some of DiaMedica Therapeutics' key competitors?

What other stocks do shareholders of DiaMedica Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Amarin (AMRN), Oncolytics Biotech (ONCY), vTv Therapeutics (VTVT), Adamis Pharmaceuticals (ADMP), Crispr Therapeutics (CRSP), Seelos Therapeutics (SEEL) and Vaxart (VXRT).

Who are DiaMedica Therapeutics' key executives?

DiaMedica Therapeutics' management team includes the following people:
  • Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)
  • Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)
  • Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 57)
  • Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)
  • Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49)

When did DiaMedica Therapeutics IPO?

(DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at a price of $4.00-$5.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

What is DiaMedica Therapeutics' stock symbol?

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

How do I buy shares of DiaMedica Therapeutics?

Shares of DMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is DiaMedica Therapeutics' stock price today?

One share of DMAC stock can currently be purchased for approximately $6.75.

How big of a company is DiaMedica Therapeutics?

DiaMedica Therapeutics has a market capitalization of $95.44 million and generates $500,000.00 in revenue each year. The company earns $-10,650,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. DiaMedica Therapeutics employs 9 workers across the globe.

What is DiaMedica Therapeutics' official website?

The official website for DiaMedica Therapeutics is www.diamedica.com.

How can I contact DiaMedica Therapeutics?

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company can be reached via phone at 763-312-6755 or via email at [email protected]

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.